379 related articles for article (PubMed ID: 28619755)
1. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer.
Railkar R; Krane LS; Li QQ; Sanford T; Siddiqui MR; Haines D; Vourganti S; Brancato SJ; Choyke PL; Kobayashi H; Agarwal PK
Mol Cancer Ther; 2017 Oct; 16(10):2201-2214. PubMed ID: 28619755
[TBL] [Abstract][Full Text] [Related]
2. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).
Siddiqui MR; Railkar R; Sanford T; Crooks DR; Eckhaus MA; Haines D; Choyke PL; Kobayashi H; Agarwal PK
Sci Rep; 2019 Feb; 9(1):2084. PubMed ID: 30765854
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Early Therapeutic Effects after Near-Infrared Photoimmunotherapy (NIR-PIT) Using Luciferase-Luciferin Photon-Counting and Fluorescence Imaging.
Maruoka Y; Nagaya T; Nakamura Y; Sato K; Ogata F; Okuyama S; Choyke PL; Kobayashi H
Mol Pharm; 2017 Dec; 14(12):4628-4635. PubMed ID: 29135265
[TBL] [Abstract][Full Text] [Related]
4. Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.
Sato K; Watanabe R; Hanaoka H; Harada T; Nakajima T; Kim I; Paik CH; Choyke PL; Kobayashi H
Mol Oncol; 2014 May; 8(3):620-32. PubMed ID: 24508062
[TBL] [Abstract][Full Text] [Related]
5. Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.
Okada R; Kato T; Furusawa A; Inagaki F; Wakiyama H; Fujimura D; Okuyama S; Furumoto H; Fukushima H; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Aug; 71(8):1877-1887. PubMed ID: 35013765
[TBL] [Abstract][Full Text] [Related]
6. Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer.
Nakamura Y; Ohler ZW; Householder D; Nagaya T; Sato K; Okuyama S; Ogata F; Daar D; Hoa T; Choyke PL; Kobayashi H
Mol Cancer Ther; 2017 Feb; 16(2):408-414. PubMed ID: 28151706
[TBL] [Abstract][Full Text] [Related]
7. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
8. Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes.
Hirata H; Kuwatani M; Nakajima K; Kodama Y; Yoshikawa Y; Ogawa M; Sakamoto N
Cancer Sci; 2021 Feb; 112(2):828-838. PubMed ID: 33345417
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials.
Okada R; Furusawa A; Vermeer DW; Inagaki F; Wakiyama H; Kato T; Nagaya T; Choyke PL; Spanos WC; Allen CT; Kobayashi H
EBioMedicine; 2021 May; 67():103345. PubMed ID: 33933782
[TBL] [Abstract][Full Text] [Related]
10. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.
Nagaya T; Sato K; Harada T; Nakamura Y; Choyke PL; Kobayashi H
PLoS One; 2015; 10(8):e0136829. PubMed ID: 26313651
[TBL] [Abstract][Full Text] [Related]
11. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer.
Harada T; Nakamura Y; Sato K; Nagaya T; Okuyama S; Ogata F; Choyke PL; Kobayashi H
Oncotarget; 2016 Nov; 7(48):79408-79416. PubMed ID: 27765903
[TBL] [Abstract][Full Text] [Related]
12. Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin-Antibody Conjugate.
Nagaya T; Gorka AP; Nani RR; Okuyama S; Ogata F; Maruoka Y; Choyke PL; Schnermann MJ; Kobayashi H
Mol Cancer Ther; 2018 Mar; 17(3):661-670. PubMed ID: 29237807
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of tumor photoimmunotherapy: Evidence of photosensitized tumor necrosis and hemodynamic changes.
Kishimoto S; Oshima N; Yamamoto K; Munasinghe J; Ardenkjaer-Larsen JH; Mitchell JB; Choyke PL; Krishna MC
Free Radic Biol Med; 2018 Feb; 116():1-10. PubMed ID: 29289705
[TBL] [Abstract][Full Text] [Related]
14. Selective Photokilling of Colorectal Tumors by Near-Infrared Photoimmunotherapy with a GPA33-Targeted Single-Chain Antibody Variable Fragment Conjugate.
Wei D; Tao Z; Shi Q; Wang L; Liu L; She T; Yi Q; Wen X; Liu L; Li S; Yang H; Jiang X
Mol Pharm; 2020 Jul; 17(7):2508-2517. PubMed ID: 32396000
[TBL] [Abstract][Full Text] [Related]
15. Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700.
Takao S; Fukushima H; King AP; Kato T; Furusawa A; Okuyama S; Kano M; Choyke PL; Escorcia FE; Kobayashi H
Cancer Sci; 2023 Dec; 114(12):4654-4663. PubMed ID: 37817415
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases.
Inagaki FF; Wakiyama H; Furusawa A; Okada R; Kato T; Fujimura D; Okuyama S; Fukushima H; Takao S; Choyke PL; Kobayashi H
Biomed Pharmacother; 2023 Apr; 160():114390. PubMed ID: 36791566
[TBL] [Abstract][Full Text] [Related]
17. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.
Mitsunaga M; Nakajima T; Sano K; Kramer-Marek G; Choyke PL; Kobayashi H
BMC Cancer; 2012 Aug; 12():345. PubMed ID: 22873679
[TBL] [Abstract][Full Text] [Related]
18. Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models.
Moore LS; de Boer E; Warram JM; Tucker MD; Carroll WR; Korb ML; Brandwein-Gensler MS; van Dam GM; Rosenthal EL
Cancer Med; 2016 Jul; 5(7):1526-34. PubMed ID: 27167827
[TBL] [Abstract][Full Text] [Related]
19. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity.
Nakajima T; Sato K; Hanaoka H; Watanabe R; Harada T; Choyke PL; Kobayashi H
BMC Cancer; 2014 May; 14():389. PubMed ID: 24885589
[TBL] [Abstract][Full Text] [Related]
20. Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT.
Nagaya T; Nakamura Y; Okuyama S; Ogata F; Maruoka Y; Choyke PL; Allen C; Kobayashi H
Mol Cancer Res; 2017 Dec; 15(12):1667-1677. PubMed ID: 28923838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
